Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 2/20 | 0.31 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29611434 | 1.00 | HDAC1 (0.35) | HDAC1HDAC6PDE3BPDE3AKDM1A | |
| SCHEMBL8847064 | 0.75 | ACHE (0.35) | HDAC1HDAC6ACHE | |
| SCHEMBL8909014 | 0.75 | CYP1A2 (0.38) | PDE3BPDE3ACYP1A2 | |
| SCHEMBL29863478 | 0.74 | CYP3A4 (0.32) | CYP1A2 | |
| SCHEMBL28341279 | 0.74 | RAPGEF4 (0.34) | KDM1AKDM1BACHE | |
| SCHEMBL23249000 | 0.74 | CYP3A4 (0.32) | CYP1A2 | |
| SCHEMBL356846 | 0.74 | TSHR (0.40) | PDE3BPDE3ACYP1A2 | |
| SCHEMBL19624709 | 0.72 | ALDH1A1 (0.33) | PDE3BPDE3ACYP1A2 | |
| Phosphine SCHEMBL27772308 | 0.72 | ACHE (0.33) | HDAC1HDAC6ACHE | |
| SCHEMBL16485488 | 0.72 | ACHE (0.33) | HDAC1HDAC6ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4559525-A2 | INHIBITING HUMAN INTEGRIN ALPHA4BETA7 | Morphic Therapeutic, Inc. (US) | 2025-05-28 | — | — | EP | disclosed |
| EP-4045039-B1 | INHIBITING HUMAN INTEGRIN ALPHA4BETA7 | MORPHIC THERAPEUTIC INC (US) | 2025-04-23 | — | — | EP | disclosed |
| US-20240174632-A1 | INHIBITING HUMAN INTEGRIN (ALPHA-4) (BETA-7) | MORPHIC THERAPEUTIC, INC. (US) | 2024-05-30 | — | — | US | disclosed |
| CN-116783161-A | Inhibition of human integrin A4B7 | 莫菲克医疗股份有限公司 | 2023-09-19 | — | — | CN | disclosed |
| EP-4228634-A1 | INHIBITING HUMAN INTEGRIN A4B7 | Morphic Therapeutic, Inc. (US) | 2023-08-23 | — | — | EP | disclosed |
| CN-115087444-A | Inhibition of human integrin alpha 4 β 7 | 莫菲克医疗股份有限公司 | 2022-09-20 | — | — | CN | disclosed |
| EP-4045039-A1 | INHIBITING HUMAN INTEGRIN ALPHA4BETA7 | Morphic Therapeutic, Inc. (US) | 2022-08-24 | — | — | EP | disclosed |
| US-11370773-B1 | Inhibiting human integrin (alpha-4) (beta-7) | MORPHIC THERAPEUTIC, INC. (US) | 2022-06-28 | — | — | US | disclosed |
| WO-2022081983-A1 | INHIBITING HUMAN INTEGRIN A4B7 | MORPHIC THERAPEUTIC, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| WO-2022081983-A1 | INHIBITING HUMAN INTEGRIN A4B7 | MORPHIC THERAPEUTIC, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| WO-2021076890-A1 | INHIBITING HUMAN INTEGRIN α4β7 | MORPHIC THERAPEUTIC, INC. (US) | 2021-04-22 | — | — | WO | disclosed |
| WO-2021076890-A1 | INHIBITING HUMAN INTEGRIN α4β7 | MORPHIC THERAPEUTIC, INC. (US) | 2021-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11370773-B1 | Inhibiting human integrin (alpha-4) (beta-7) | ITGB7, ITGB4, ITGA4 | HDAC1 539/4885HDAC6 173/4885PDE3B 1126/4885 |
| US-20240174632-A1 | INHIBITING HUMAN INTEGRIN (ALPHA-4) (BETA-7) | ITGB7, ITGB4, ITGA4 | HDAC1 539/4885HDAC6 173/4885PDE3B 1126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.